{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-072753","form_type":"8-K","ticker":null,"cik":"0001621227","company_name":"Adaptimmune Therapeutics PLC","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.499297+00:00","generated_at":"2026-05-17T22:19:46.110750+00:00","sec_items":["1.02","2.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Adaptimmune sells cell therapy assets to US WorldMeds for $55M cash plus $30M milestones","bullets":["Sold TECELRA, lete-cel, afami-cel, uza-cel to US WorldMeds subsidiary; $55M upfront, up to $30M in milestones.","Hercules Capital loan of $29.1M paid off, terminating the Loan and Security Agreement.","Pro forma net gain on sale estimated at $134M after tax; FY2024 pro forma net income of $159.6M vs prior loss.","Milestones: $5M on lete-cel BLA acceptance, $10M on FDA approval, up to $5M on TECELRA revenue thresholds.","Pro forma cash increases to $91M from $41M; equity turns positive to $96.7M from negative $37.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-072753","json":"https://secwatch.observer/filing/0001104659-25-072753.json","markdown":"https://secwatch.observer/filing/0001104659-25-072753.md","text":"https://secwatch.observer/filing/0001104659-25-072753.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925072753/0001104659-25-072753-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925072753/tm2522092d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:19:46.110750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"558990b9722816b91a1bbdb4ec42f6f5eade0c3b","claim":"Adaptimmune Therapeutics PLC completed a disposition involving USWM CT, LLC, a subsidiary of US WorldMeds Partners, LLC for $55 million in cash upon consummation of the Transaction, and Purchaser has agreed to make future payments of up to $30 million (closed 2025-07-31).","evidence_excerpt":"rights, regulatory authorizations, contracts, equipment, inventory, and other related assets (together with the Products, the “Transferred Assets”). Purchaser paid Adaptimmune $55 million in cash upon consummation of the Transaction, and Purchaser has agreed to make future payments of up to $30 million to Adaptimmune upon the achievement of certain regulatory and","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621227/000110465925072753/0001104659-25-072753-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"USWM CT, LLC, a subsidiary of US WorldMeds Partners, LLC"},{"label":"Consideration","value":"$55 million in cash upon consummation of the Transaction, and Purchaser has agreed to make future payments of up to $30 million"},{"label":"Closing","value":"2025-07-31"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}